Anthracycline‑based induction chemotherapy followed by concurrent cyclophosphamide, methotrexate and 5‑fluorouracil and radiation therapy in surgically resected axillary node‑positive breast cancer

Recchia,Francesco; Candeloro,Giampiero; Cesta,Alisia; Di Staso,Mario; Bonfili,Pierluigi; Gravina,Giovanni Luca; Di Cesare,Ernesto; Necozione,Stefano; Rea,Silvio

doi:10.3892/mco.2014.269

Anthracycline‑based induction chemotherapy followed by concurrent cyclophosphamide, methotrexate and 5‑fluorouracil and radiation therapy in surgically resected axillary node‑positive breast cancer

Authors:
- Francesco Recchia
- Giampiero Candeloro
- Alisia Cesta
- Mario Di Staso
- Pierluigi Bonfili
- Giovanni Luca Gravina
- Ernesto Di Cesare
- Stefano Necozione
- Silvio Rea
View Affiliations

Affiliations: Department of Medical Oncology, Civilian Hospital, 67051 Avezzano, L'Aquila, Italy, Laboratory of Radiobiology and Division of Radiotherapy, Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, 67100 L'Aquila, L'Aquila, Italy, Department of Clinical Epidemiology, University of L'Aquila, 67100 L'Aquila, L'Aquila, Italy, Department of Surgical Oncology, University of L'Aquila, 67100 L'Aquila, L'Aquila, Italy
Published online on: March 21, 2014 https://doi.org/10.3892/mco.2014.269
Pages: 473-478

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to determine the toxicity and efficacy of 4 courses of anthracyclines‑taxane (AT) chemotherapy followed by radiation therapy (XRT) concurrent with cyclophosphamide, methotrexate and 5‑fluorouracil (CMF) in surgically resected axillary node‑positive (N+) breast cancer. A total of 200 women with N+ breast cancer were treated with adriamycin and docetaxel followed by XRT concurrent with six courses of CMF. Two courses of dose‑dense chemotherapy with ifosfamide, carboplatin and etoposide, supported by pegfilgrastim, were administered to patients with >5 histologically confirmed axillary lymph node metastases and patients with triple‑negative disease. Additional treatments included 1 year of trastuzumab in human epidermal growth factor receptor 2‑positive patients, 5 years of a luteinizing hormone‑releasing hormone analogue in premenopausal women and 5 years of an aromatase inhibitor (AI) in estrogen receptor‑positive (ER+) patients. The mean number of positive axillary lymph nodes was 4.4 (range, 2‑37), 52% of the patients were premenopausal, 74% were ER+ and 26% had triple‑negative disease. After a median follow‑up of 73 months, grade 2 and 3 hematological toxicity was observed in 20% of the patients. The 10‑year disease‑free survival (DFS) and overall survival (OS) rates were 73 and 77%, respectively. There was no significant difference in DFS between ER+ and estrogen receptor‑negative (ER‑) patients (P>0.05), whereas the OS was better in ER+ vs. ER‑ patients (P<0.05) and in premenopausal vs. postmenopausal patients (P<0.005). In conclusion, induction AT concurrent CMF and XRT and dose‑dense chemotherapy followed by AI in N+ high‑risk breast cancer was associated with a low level of systemic and late cardiac toxicity and excellent local control, DFS and OS.

View Figures

View References

1.	Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M and Marubini E: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 347:1227–1232. 2002.PubMed/NCBI
2.	Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH and Wolmark N: Twenty year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 347:1233–1241. 2002.PubMed/NCBI
3.	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365:1687–1717. 2005.PubMed/NCBI
4.	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Peto R, Davies C, Godwin J, et al: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 379:432–444. 2012. View Article : Google Scholar : PubMed/NCBI
5.	Darby SC, Ewertz M, McGale P, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 368:987–998. 2013. View Article : Google Scholar : PubMed/NCBI
6.	Recht A, Come SE, Gelman RS, et al: Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage, node-positive breast cancer: sequencing, timing, and outcome. J Clin Oncol. 9:1662–1667. 1991.PubMed/NCBI
7.	Toledano A, Azria D, Garaud P, Fourquet A, Serin D, Bosset JF, Miny-Buffet J, Favre A, Le Floch O and Calais G: Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol. 25:405–410. 2007. View Article : Google Scholar
8.	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Darby S, McGale P, Correa C, et al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 378:1707–1716. 2011.
9.	Rodenhuis S, Bontenbal M, Beex LV, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 349:7–16. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Recchia F, Nuzzo A, Lalli A, De Filippis S and Torchio P: Activity of standard-dose carboplatin, cyclophosphamide, and etoposide in patients with metastatic breast cancer with previous exposure to anthracyclines. Am J Clin Oncol. 20:166–168. 1997. View Article : Google Scholar : PubMed/NCBI
11.	Recchia F, De Fillipis S, Piccinini M and Rea S: High-dose carboplatin, cyclophosphamide, etoposide with hematological growth factors, without stem cell support in patients with advanced cancer. Anticancer Res. 23:4141–4147. 2003.PubMed/NCBI
12.	Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G and Rea S: Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 106:514–523. 2006. View Article : Google Scholar
13.	Recchia F, Candeloro G, Desideri G, Necozione S, Recchia CO, Cirulli V and Rea S: Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study. Cancer Med. 1:89–95. 2012. View Article : Google Scholar : PubMed/NCBI
14.	Simon R: Confidence intervals for reporting results of clinical trials. Ann Intern Med. 105:429–435. 1986. View Article : Google Scholar : PubMed/NCBI
15.	Kaplan EL and Meyer P: Nonparametric estimation from incomplete observation. J Am Stat Assoc. 53:457–481. 1958. View Article : Google Scholar
16.	Cox DR: Regression models and Life-Tables. J R Stat Soc. 34:187–220. 1972.
17.	Hartsell WF, Recine DC, Griem KL and Murthy AK: Delaying the initiation of intact breast irradiation for patients with lymph node positive breast cancer increases the risk of local recurrence. Cancer. 76:2497–2503. 1995. View Article : Google Scholar : PubMed/NCBI
18.	Buchholz TA, Austin-Seymour MM, Moe RE, Ellis GK, Livingston RB, Pelton JG and Griffin TW: Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys. 26:23–35. 1993. View Article : Google Scholar : PubMed/NCBI
19.	Hickey BE, Francis DP and Lehman M: Sequencing of chemotherapy and radiotherapy for early breast cancer. Cochrane Database Syst Rev. 4: View Article : Google Scholar
20.	Moebus V, Jackisch C, Lueck HJ, et al: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol. 28:2874–2880. 2010. View Article : Google Scholar
21.	Recchia F, Candeloro G, Necozione S, Desideri G, Cesta A, Recchia L and Rea S: Vascular endothelial growth factor expression and T-regulatory cells in premenopausal breast cancer. Oncol Lett. 5:1117–1122. 2013.PubMed/NCBI
22.	Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M and Hankinson SE: Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 98:1406–1415. 2006. View Article : Google Scholar : PubMed/NCBI